Molecules
April 13, 2022
Henry Lowe, Ngeh J. Toyang, Blair Steele et al.
53 citations
The word “psychedelic” (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Osmond in 1956, who had been conducting research on lysergic acid diethylamide (LSD) at the time. Psychedelic drugs such as N,N-DMT/DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), LSD (lysergic acid diethylamide), MDMA...
Psychiatric News
April 1, 2022
Michael Avissar, A. J. Ambrose
A growing body of research suggests that psychedelic compounds may be useful for treating patients with certain disorders. As highlighted by several sessions at the APA Annual meeting, there’s a growing renewed interest in psychedelics, which are compounds that induce changes in thought, perception, and mood, in the clinical and research communities. Classic psychedelics refer to a subset whose...
Frontiers in Epidemiology
March 23, 2022
Alan K. Davis, Brooke J. Arterberry, Yitong Xin et al.
20 citations
Background The current study is one of the first to examine race, ethnic, and sex differences in the prevalence of and trends in hallucinogen use among lifetime users in the United States. Methods Data came from the 2015–2019 National Survey on Drug Use and Health and included respondent's reporting ever-using hallucinogens ( n = 41,060; female = 40.4%). Descriptive and multinomial logistic...
C&EN Global Enterprise
March 7, 2022
Bethany Halford
Over the past decade, psychedelic compounds like psilocybin and ecstasy have emerged as potentially life-changing treatments for mental illnesses, including major depressive disorder and posttraumatic stress disorder. Read on to learn how some companies are trying to bring these once-demonized drugs to market and how others are hoping to use chemistry to eliminate their hallucinogenic effects—a...
Frontiers in Psychology
March 4, 2022
Agnieszka D. Sekula, Luke A. Downey, Prashanth Puspanathan
27 citations
Psychotherapy with the use of psychedelic substances, including psilocybin, lysergic acid diethylamide (LSD), ketamine, and 3,4-methylenedioxymethamphetamine (MDMA), has demonstrated promise in treatment of post-traumatic stress disorder (PTSD), anxiety, addiction, and treatment-resistant depression. Psychedelic-assisted psychotherapy (PP) represents a unique psychopharmacological model that...
Journal of Psychopharmacology
March 1, 2022
Catherine Bird, A. H. Young
As we head into the (Northern Hemisphere) spring, the Journal publishes another set of papers which illustrate the robust health of the science of psychopharmacology. Once again, papers mostly focus on psychedelic drugs and related topics reflecting the zeitgeist (Young, 2022). de Wit et al. (2022) explore translational challenges and opportunities between clinical research and laboratory...
Neuropsychopharmacology
March 1, 2022
Deborah Rudin, John D. Mccorvy, Grant C. Glatfelter et al.
18 citations
Derivatives of (2-aminopropyl)indole (API) and (2-aminopropyl)benzofuran (APB) are new psychoactive substances which produce stimulant effects in vivo. (2-Aminopropyl)benzo[β]thiophene (APBT) is a novel sulfur-based analog of API and APB that has not been pharmacologically characterized. In the current study, we assessed the pharmacological effects of six APBT positional isomers in vitro, and...
Sexual & Relationship Therapy
February 28, 2022
Lucy Jacobs, S. Banbury, J. Lusher
Abstract Background: Research has predominated among the therapeutic application of psychedelics for varied psychopathologies and yet remains limited when supporting sexual behaviour intimacy among couples; particularly those who micro-dose. Method: Using semi-structured interviews, this qualitative study explored the micro-dosing sexual experiences of four partnered men and women aged 20–35...
Frontiers in Behavioral Neuroscience
February 10, 2022
Matthew B Pomrenze, Franciely Paliarin, Rajani Maiya
27 citations
Substance use disorders in humans have significant social influences, both positive and negative. While prosocial behaviors promote group cooperation and are naturally rewarding, distressing social encounters, such as aggression exhibited by a conspecific, are aversive and can enhance the sensitivity to rewarding substances, promote the acquisition of drug-taking, and reinstate drug-seeking. On...
Expert Opinion on Investigational Drugs
February 1, 2022
Lynnette A. Averill, Chadi G. Abdallah
The unfortunate reality of the mental health crisis plaguing much of the world, in tandem with and exacerbated by the COVID-19 pandemic [1–3], highlights the limited effective pharmacologic treatments in our toolbox for posttraumatic stress disorder (PTSD). There are only two FDA-approved medications indicated for PTSD, both selective serotonin reuptake inhibitors (SSRIs). Though these...